No Data
Hong Kong stocks move | INNOVENT BIO (01801) opened nearly 4% higher after earnings, with annual net losses narrowing by 90.8% year-on-year, and major products like Dabaoshu maintain strong revenue growth.
INNOVENT BIO (01801) opened nearly 4% higher after its performance announcement. As of the time of writing, it rose by 3.97%, priced at 40.6 Hong Kong dollars, with a transaction volume of 20.9496 million Hong Kong dollars.
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
SAN FRANCISCO and SUZHOU, China, March 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and
Hong Kong Stock Morning Report | Trump swings the tariff stick, JPMorgan raises the target for Chinese Stocks.
① The President of the USA, Trump, announced a 25% tariff on all imported Autos. ② The USA has placed several Chinese entities on the export control "entity list"; the Ministry of Foreign Affairs and the Ministry of Commerce have spoken out. ③ The three major Indexes of the USA stock market closed lower, with most China Concept Stocks declining. ④ As the countdown to Trump's tariff enforcement begins, two Federal Reserve officials issue warnings of impact. ⑤ JPMorgan follows up by raising the target for China Stocks.
INNOVENT BIO (01801.HK) has impressive performance in the 2024 fiscal year: with revenue reaching a record high of 9.42 billion yuan, the oncology brand leads the market.
Gelonghui March 26丨INNOVENT BIO (01801.HK) announced its annual performance for 2024. As a leading biopharmaceutical company in China, under the drive of the "sustainable growth" and "Global Strategy" strategies, the company achieved Non-IFRS annual profitability for the first time in 2024, solidified its leading position in the oncology field, fully realized the milestones of its late-stage pipeline, and further enhanced its innovative R&D capabilities. 2024 is a milestone year in the company's development history. Looking ahead, 2025 will be a critical year for the company to enter a new era of dual-driven and Global innovation development, further unlocking upward potential.
Highlights of INNOVENT BIO's performance for the year 2024.
Achieved profitability for the first time, entering a new era of dual-driven and Global development. San Francisco, USA, and Suzhou, China, March 26, 2025 /PR Newswire/ -- INNOVENT BIO, a biopharmaceutical company dedicated to the research, development, production, and sales of Innovative Drugs in the fields of major diseases such as oncology, metabolism, cardiovascular, autoimmune, and ophthalmology, has announced its 2024 performance, reporting on the company's Business advancements, financial performance, and medium to long-term Global Strategy. Dr. Yu Dechao, founder, Chairman, and CEO of INNOVENT BIO, stated: "As the leader in China's Biopharmaceutical Industry.
Express News | Innovent Announces 2024 Annual Results and Business Updates
